The discussion on biomarker testing practices for patients with non–small cell lung cancer turns its focus to the metastatic setting.
Intricacies of EGFR-Mutated NSCLC Care From the Patient Perspective
Alexander Spira, MD, and Julia Lazo, RN, spoke with Melinda Reubens, who was diagnosed with EGFR-mutant NSCLC, and her husband Justin.
Navigating Management and Dosing Considerations for Amivantamab in NSCLC
Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.
Updated Results Show THIO/Cemiplimab Improves Median OS in Advanced NSCLC
6-thio-2’-deoxyguanosine sequenced plus cemiplimab elicited an OS of 16.9 months in the third-line setting for patients with advanced non–small cell lung cancer.
Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology
Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.
Zipalertinib Meets Primary ORR End Point in EGFR exon 20 NSCLC
Full results from the phase 1/2 REZILIENT1 trial evaluating zipalertinib in NSCLC will be shared at a future medical conference.
Enhanced Postoperative Recovery May Improve Outcomes in Elderly NSCLC
Postoperative pulmonary complications were reduced with enhanced recovery after surgery vs control in elderly patients with non–small cell lung cancer.